- The key vendors in the Global Multiple Myeloma Drugs Market 2015-2019 are Celgene Corp., Johnson & Johnson, Novartis AG, Onyx Pharmaceuticals Inc., Sanofi SA and Takeda Pharmaceutical Co. Ltd.
London, 25 November 2014: TechNavio, an independent tech-focused global research firm, has announced the publication of its market research report on the Global Multiple Myeloma Drugs Market 2015-2019. One of the major trends being witnessed in this market is increased awareness about multiple myeloma among the medical fraternity, patients, and the families of patients, which enhances the number of treatment-seeking patients, which results in an increase in the overall consumption of medicines. The Global Multiple Myeloma Drugs market is expected to grow at a CAGR of 8.50 percent during the period 2014-2019.
Multiple myeloma is characterized by the malignancy of plasma cells, a type of white blood cells. Malignant plasma cells undergo overproduction of a defective protein, which accumulates in the bone marrow forming multiple tumors. This leads to a weakened immune system and causes kidney and bone problems and anemia.
“The primary idea behind sequential therapy is to reduce the toxic effect of combination therapy,” says Faisal Ghaus, Vice President of TechNavio Research.
“Clinical trials are ongoing to obtain more knowledge about the safety and efficacy parameters of the sequential treatment.”
To define the market conditions in the next 3-4 years, TechNavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
